Search clinical trials for: Not suitable for local treatment with curative intent

Total 415743 results

European Organisation for Research and Treatment...

Completed

Early Compared With Delayed Hormone Therapy in Treating Patients With Nonmetastatic Prostate Cancer

Neoplasm, Prostate
Liaoning Tumor Hospital & Institute

Not yet recruiting

Quintuple Method for Treatment of Multiple Refractory Colorectal Liver Metastases

For Patients With Colorectal Cancer Liver Metastases Who Were Not Able to Curative Surgical Resection.Focused on the Treatment Effect With the Quintuple Method

China
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

Plasma Cell Myeloma

United States
Xiangya Hospital of Central South University

Recruiting

Adjuvant Immunotherapy With Toripalimab Following Curative-intent Ablation for Recurrent Hepatocarcinoma

Hepatocellular Carcinoma

China
National Cancer Institute (NCI)

Recruiting

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Pancreatic Acinar Cell Carcinoma | Pancreatic Adenosquamous Carcinoma | Pancreatic Squamous Cell Carcinoma | Resectable Pancreatic Acinar Cell Carcinoma | Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Adenosquamous Carcinoma | Resectable Pancreatic Carcinoma

United States
AstraZeneca

Active, not recruiting

Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC (SELECT-1)

Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV

United States, Canada, France, Italy, Spain, United Kingdom, Belgium, Poland, Brazil, Germany, Hungary, Peru, Russian Federation, Turkey, Australia, Chile, Austria, Netherlands, Portugal, Israel, Mexico, Romania, Sweden, Ukraine, Bulgaria, Argenti...
Universitätsklinikum Hamburg-Eppendorf
Cancer Research UK; Deutsche Krebshilfe e.V., Bonn (Germany); Australasian Gastro-Intestinal... and other collaborators

Active, not recruiting

Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer (ACTICCA-1)

Cholangiocarcinoma | Gall Bladder Carcinoma

Germany, Netherlands, United Kingdom, Australia, Denmark, Italy, New Zealand, Austria
Celgene

Completed

Phase II Safety and Tolerability Trial With Nab-Paclitaxel Plus Carboplatin Followed by Nab-Paclitaxel for First Line Treatment of NSCLC Subjects With ECOG PS 2 (AboundPS2)

Carcinoma, Non-Small-Cell Lung

United States
Pfizer

Completed

A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung (PROFILE 1014)

Non Squamous Lung Cancer

United States, Switzerland, Taiwan, Spain, Korea, Republic of, Canada, United Kingdom, Singapore, Japan, Germany, Luxembourg, Australia, France, Brazil, Italy, Hong Kong, China, Belgium, Russian Federation, Austria, Finland, Portugal and more
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Withdrawn

Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment

Stage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Rectal Adenocarcinoma

United States
Novartis Pharmaceuticals

Completed

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Endometrial Cancer | VEGF | Solid Tumors and Advanced Endometrial Cancer | Second-line Treatment

Italy, United Kingdom, Spain, Brazil, United States, Korea, Republic of, New Zealand
Meir Medical Center

Completed

Study of Erlotinib With Docetaxel in Selected Non Small Cell Lung Cancer Patients in First Line Treatment

Non-Small Cell Lung Cancer

Israel
Eli Lilly and Company

Completed

Study of Pemetrexed Versus Pemetrexed Plus Erlotinib as Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC)

Histological or Cytological Diagnosis of Locally Advanced or Metastatic NSCLC of Nonsquamous Histology and Not Amenable to Curative Therapy.

Hungary, Germany, Austria, Spain, Sweden
Region Skane
Lund University; Linkoeping University

Recruiting

Brief Admission by Self-referral for Individuals With Self-harm: Effects on Compulsory Care

Suicide, Attempted | Suicide | Borderline Personality Disorder | Self-harm | Emergency Psychiatric | Self-injury | Hospitalizations Psychiatric

Sweden
Guangdong Provincial People's Hospital

Not yet recruiting

PCSK9 Inhibitors in Combination With Advanced Treatment Strategies for the Treatment of Advanced Colorectal Cancer With pMMR/MSS

Colorectal Cancer
ImmunoGen, Inc.

Not yet recruiting

A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

Recurrent Ovarian Cancer | Folate Receptor-Alpha Positive

United States, Spain, Australia, Belgium, Canada, France, Ireland, Italy
Hutchmed

Recruiting

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer

China
Sun Jing

Not yet recruiting

Nocardia Rubra Cell Wall Skeleton in Combination With Prior Second- or Third-line Regimens for the Treatment of Potentially Hazardous Colorectal Cancer SD Status

Colorectal Neoplasms | Colorectal Cancer
Rennes University Hospital

Not yet recruiting

Medico-economic Evaluation of Robot-assisted Laparoscopy Compared With Conventional Laparoscopy in Hysterectomy for Endometrial Cancer. (ROBOT-ECO-GYN)

Hysterectomies for Low- or Intermediate-risk Endometrial Carcinoma

France
Biotech Pharmaceutical Co., Ltd.

Not yet recruiting

Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer (NOTABLE-308)

Refractory Metastatic Colorectal Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma

Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

China
Chinese PLA General Hospital

Not yet recruiting

A Clinical Study of Adebrelimab Combined With Apatinib and Paclitaxel in Patients With Advanced Gastric Cancer.

Gastric Cancer
Hunan Cancer Hospital

Not yet recruiting

Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure

Melanoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC)

Biliary Tract Cancer | Gemox Chemotherapy

China
Zhejiang Cancer Hospital

Not yet recruiting

Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial

Metastatic Breast Cancer

China
Nanfang Hospital, Southern Medical University

Not yet recruiting

Cadonilimab Plus CapeOX as First-Line Treatment for Advanced GC/GEJC With High TMEscore

Gastric Cancer

China
Nanfang Hospital, Southern Medical University

Recruiting

Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore

Gastric Cancer

China
October 6 University
Cairo University

Recruiting

Efficacy of Probiotic Capsules With Topical Clobetasol Propionate in OLP Treatment

Oral Lichen Planus

Egypt
Vrije Universiteit Brussel
University of British Columbia; University of Coimbra; Amsterdam UMC, location... and other collaborators

Not yet recruiting

International Study to Evaluate a Navigation Program for Older People With Cancer and Their Family Caregivers (EU NAVIGATE Study) (EU NAVIGATE)

Cancer (Active Cancer, Meaning Not Being Cancer Free), of Any Stage and Involving Any Treatment/Care Regimen; i.e. Curative, Life-extending, or Palliative
Pfizer

Recruiting

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Advanced or Metastatic Breast Cancer

United States, Taiwan, China, Japan, Canada, Israel, Korea, Republic of, Argentina, Australia, Brazil
Tonix Pharmaceuticals, Inc.
National Institute on Drug Abuse (NIDA); Premier

Not yet recruiting

Comparing Efficacy & Safety Of TNX-1300 To Placebo With UC For Treatment Of Acute Cocaine Intoxication In ED Subjects (CATALYST) (CATALYST)

Cocaine Use | Cocaine Abuse | Cocaine Adverse Reaction | Cocaine Intoxication | Cocaine Toxicity
Aadi Bioscience, Inc.

Recruiting

Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

Neuroendocrine Tumors | Pancreatic Neuroendocrine Tumor | Gastrointestinal Neuroendocrine Tumor | NET | Pulmonary Neuroendocrine Tumor

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Geriatric Care Survivorship Intervention for Improving the Overall Health of Older Adults With Stage I-III Breast Cancer Who Have Completed Curative Treatment

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
First Affiliated Hospital of Jinan University; Shenzhen University General...

Recruiting

Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Carcinoma | Digestive System Neoplasms | Intrahepatic Cholangiocarcinoma | First-line Treatment | PD-1 Inhibitor

China
Hirva Mamdani
AstraZeneca; Barbara Ann Karmanos Cancer Institute

Recruiting

MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer (MOZART)

Small Cell Lung Cancer | SCLC | Extensive Stage Small Cell Lung Cancer

United States
AGO Research GmbH

Not yet recruiting

Pembrolizumab in Combination With Lenvatinib in Patients With Recurrent, Persistent, Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy (PIERCE)

Recurrent Vulvar Cancer | Persistent Vulvar Cancer | Metastatic Vulva Cancer | Locally Advanced Vulvar Cancer
Shanghai JMT-Bio Inc.

Not yet recruiting

Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.

First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer
AstraZeneca

Recruiting

Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) (TOURMALINE)

Biliary Tract Cancer

France, Spain, Italy, Korea, Republic of, Japan, Germany, United States, Singapore
Hellenic Cooperative Oncology Group

Recruiting

Durvalumab in Combination With Standard Chemotherapy of Patients With Extensive Stage Small Cell Lung Cancer (DRIVE)

Small-cell Lung Cancer | Extensive-stage Small-cell Lung Cancer

Greece
Nanfang Hospital of Southern Medical University

Recruiting

Alternating Treatment With Fruquintinib and Bevacizumab Plus Capecitabine as Maintenance Therapy After First-Line Treatment in Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Beijing Shenogen Biomedical Co., Ltd

Recruiting

Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP) (BESTPOP)

Hepatocellular Carcinoma

China
Bayer

Recruiting

A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide (ARAMON)

Biochemically Recurrent Prostate Cancer

United States
European Organisation for Research and Treatment...
Breast International Group; Menarini Group

Recruiting

Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) (TREAT ctDNA)

Stage IIB Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast Cancer | Stage III Breast Cancer

Belgium, Italy, Ireland, France, Germany
Celcuity, Inc.

Recruiting

Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) (VIKTORIA-1)

Breast Cancer

Korea, Republic of, United States, Belgium, United Kingdom, Taiwan, France, Italy, Australia, Singapore, Argentina, Canada, India, Mexico, Czechia, Spain, Austria, Bulgaria, Germany, Hungary, Poland, Brazil, Greece, Romania
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) for Recurrent, Metastatic, or Unresectable HER2-Positive Salivary Gland Cancer

Recurrent Salivary Gland Carcinoma | Stage III Major Salivary Gland Cancer AJCC v8 | Stage IV Major Salivary Gland Cancer AJCC v8 | Metastatic Salivary Gland Carcinoma | Unresectable Salivary Gland Carcinoma

United States
Pfizer

Recruiting

Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan

Breast Cancer

Japan
Gilead Sciences
Merck Sharp & Dohme LLC

Recruiting

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-04)

Triple Negative Breast Cancer | PD-L1 Positive

United States, Taiwan, Belgium, Australia, Austria, Israel, Spain, Italy, Korea, Republic of, Japan, France, Netherlands, Canada, Turkey, Germany, Malaysia, Singapore, United Kingdom, Hong Kong, Hungary, Mexico, Switzerland, Puerto... and more
Gilead Sciences

Recruiting

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-03)

Triple Negative Breast Cancer | PD-L1 Negative

United States, Hong Kong, Belgium, Australia, Austria, Israel, Spain, Korea, Republic of, Taiwan, China, Japan, Netherlands, Brazil, Canada, Turkey, France, Germany, Malaysia, United Kingdom, Singapore, Hungary, Mexico, Italy, Switzer... and more
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

Efficacy, Safety and Exploratory Clinical Study of Bevacizumab Combined With Oxaliplatin and TAS-102 in First-line Treatment of Advanced Colorectal Cancer

Advanced Colorectal Cancer
Genentech, Inc.

Recruiting

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer

Korea, Republic of, United States, Spain, Taiwan, United Kingdom, Japan, Germany, Argentina, Turkey, Greece, Italy, Singapore, South Africa

Search clinical trials for: Not suitable for local treatment with curative intent

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Armenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations